Schizophrenia Clinical Trial
Official title:
Safety of Transcranial Direct Current Brain Stimulation (TDCS) for Improvement of Psychotic Symptoms and Cognitive Functioning in Childhood Onset Schizophrenia (COS)
Verified date | August 18, 2015 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will test whether transcranial direct current stimulation (TDCS) can be used
safely in children with schizophrenia and if it can improve memory and attention span or
auditory hallucinations in these children, at least temporarily. TDCS has temporarily
improved memory and attention span in healthy adults and a similar method called TMS has
relieved auditory hallucinations in adults with schizophrenia. For the TDCS procedure, the
child sits in a chair and two soft sponge electrodes are placed on the child s forehead and
held in place with a soft wrapping. One sponge electrode is placed on an arm. The electrodes
are attached to a stimulator with a wire.
Children with schizophrenia who meet the following criteria may be eligible for this study:
- Are 10 yrs or older age.
- Are participating in NIH protocol 03-M-0035.
- Are on a stable medication regimen for at least 6 months.
- Have problems with memory and attention span or have auditory hallucinations.
Participants are randomly assigned to receive either real or sham TDCS on an inpatient or
outpatient basis in 20-minute sessions daily, except weekends, for 10 days. For real TDCS,
patients receive stimulation to the front of the brain. For sham stimulation, the children
have electrodes placed on the forehead, but no actual stimulation is delivered. In addition
to TDCS, patients have the following procedures:
- Checks of blood pressure, pulse and breathing rate before, during and right after each
stimulation and again 8 hours later.
- Electrocardiogram (EKG) and electroencephalogram (EEG) before starting stimulation and
after completing the 10 days of TDCS.
- Interviews and examinations to check for side effects of TDCS.
- Pen-and-paper or computer tests of learning, attention and memory.
- At the end of the 10 sessions, children who were in the sham TDCS group are offered the
same number of sessions of active TDCS.
- Follow-up telephone call 1 month after the end of stimulation to see how the child is
doing.
- 1- to 2-day outpatient visit 6 months after the stimulation. This visit includes
interviews with the parent and the child, rating of the child s psychiatric symptoms,
and pen-and-paper or computer tests of thinking, attention and memory.
Status | Terminated |
Enrollment | 20 |
Est. completion date | August 18, 2015 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years and older |
Eligibility |
- INCLUSION CRITERIA: COS patients (age 10 and above) recruited and followed under the current protocol 03-M-0035, where subjects have been stable (in the judgment of the investigator) on their medications for 2 months with or without PRN medications but continue to experience either: 1. Cognitive difficulties as evidenced by information from parents and teachers, clinical interview, and performance (below average based on published norms for each test) on neurocognitive tests (WMS-III Spatial Span (nonverbal) and WMS-III Letter-Number Sequencing (verbal) attention/vigilance (CPT-IP), and verbal learning (HVLT-R), all sub tests of the NIMH MATRICS battery). 2. Significant auditory hallucinations as measured by SAPS (scores above 2) or BPRS (scores above 3). EXCLUSION CRITERIA: In addition to the exclusion criteria under protocol 03-M-0035, the following will be exclusionary: 1. Broken or abnormal skin in the area of the electrodes. 2. Presence of metal in the cranial cavity. 3. Holes in the skull from trauma or surgery. 4. Positive pregnancy test. 5. Presence of other psychiatric illness (e.g. severe anxiety, OCD etc) unless the patient has been on stable medication for the prior 2 months |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health (NIMH) |
United States,
Asarnow JR, Ben-Meir S. Children with schizophrenia spectrum and depressive disorders: a comparative study of premorbid adjustment, onset pattern and severity of impairment. J Child Psychol Psychiatry. 1988 Jul;29(4):477-88. — View Citation
Russell AT, Bott L, Sammons C. The phenomenology of schizophrenia occurring in childhood. J Am Acad Child Adolesc Psychiatry. 1989 May;28(3):399-407. — View Citation
Watkins JM, Asarnow RF, Tanguay PE. Symptom development in childhood onset schizophrenia. J Child Psychol Psychiatry. 1988 Nov;29(6):865-78. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | TDCS treatment is safe in childhood onset schizophrenia | |||
Secondary | Improvement in cognition and psychosis |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |